{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Neoplasm&page=9", "query": { "condition": "Solid Neoplasm", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 5454, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Neoplasm&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Neoplasm&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T20:42:13.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01466569", "title": "An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor of Epithelial Origin", "Gastric Cancer" ], "interventions": [ { "name": "AbGn-7", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbGenomics B.V Taiwan Branch", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-11", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 2, "location_summary": "Rockledge, Pennsylvania • San Antonio, Texas", "locations": [ { "city": "Rockledge", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466569" }, { "nct_id": "NCT01892046", "title": "Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "SNX-5422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esanex Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-11", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Augusta, Georgia • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01892046" }, { "nct_id": "NCT00098969", "title": "UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "resveratrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2004-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098969" }, { "nct_id": "NCT03678883", "title": "9-ING-41 in Patients With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Pancreatic Cancer", "Sarcoma", "Renal Cancer", "Refractory Cancer", "Refractory Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Pancreatic Adenocarcinoma", "Resistant Cancer", "Neoplasm Metastasis", "Neoplasm of Bone", "Neoplasm, Breast", "Neoplasm of Lung", "Neoplasms,Colorectal", "Neoplasms Pancreatic", "Malignant Glioma", "Malignancies", "Malignancies Multiple", "Bone Metastases", "Bone Neoplasm", "Bone Cancer", "Pancreas Cancer", "Pancreatic Neoplasms", "Breast Neoplasms", "Acute T Cell Leukemia Lymphoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Gemcitabine - 21 day cycle", "type": "DRUG" }, { "name": "Doxorubicin.", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Carboplatin.", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Gemcitabine - 28 day cycle", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-01-04", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03678883" }, { "nct_id": "NCT06630442", "title": "Food Safety Educational Training Program to Improve Food Safety Knowledge and Behaviors in Cancer Patients Receiving Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2022-02-21", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630442" }, { "nct_id": "NCT06136897", "title": "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-23", "completion_date": "2027-01-15", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136897" }, { "nct_id": "NCT00908024", "title": "Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Head and Neck Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "BMS-754807", "type": "DRUG" }, { "name": "cetuximab (Erbitux®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-10", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Durham, North Carolina • Madison, Wisconsin", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00908024" }, { "nct_id": "NCT00020046", "title": "Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Prostate Cancer", "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "1999-12", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020046" }, { "nct_id": "NCT06056024", "title": "A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, KRAS Mutation" ], "interventions": [ { "name": "BI 3706674", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2023-12-06", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 6, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Boston, Massachusetts + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056024" }, { "nct_id": "NCT01139346", "title": "Study of Oral Darinaparsin in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "darinaparsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-06", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-10-21T20:42:13.754Z", "location_count": 3, "location_summary": "Lafayette, Indiana • Dallas, Texas • Houston, Texas", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01139346" } ] }